Brain-Derived Neurotrophic Factor clinical trials at UCSD
1 research study open to eligible people
A Clinical Trial of AAV2-BDNF Gene Therapy in Early Alzheimer's Disease and Mild Cognitive Impairment
open to eligible people ages 50-80
This is a first-in-human clinical trial to test whether a protein administered into the brain continuously by gene therapy, Brain-Derived Neurotrophic Factor (BDNF), will slow or prevent cell loss in the brains of people affected by Alzheimer's disease and Mild Cognitive Impairment. The protein may also activate cells in the brain that have not yet deteriorated. Gene therapy refers to the use of a harmless virus to have brain cells make the potentially protective protein, BDNF.
San Diego, California and other locations
Our lead scientists for Brain-Derived Neurotrophic Factor research studies include Mark Tuszynski, M.D., Ph.D..